Kelly Phillips

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.

Lieske H Schrijver, Antonis C Antoniou, Håkan Olsson, Thea M Mooij, Marie-José Roos-Blom, Leyla Azarang, Julian Adlard, Munaza Ahmed, Daniel Barrowdale, Rosemarie Davidson, Alan Donaldson, Ros Eeles, D Gareth Evans, Debra Frost, Alex Henderson, Louise Izatt, Kai-Ren Ong, Valérie Bonadona, Isabelle Coupier, Laurence Faivre, et al.

Journal article  |  2021  |  Am J Obstet Gynecol

BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contr..

Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort.

Robert J MacInnis, Julia A Knight, Wendy K Chung, Roger L Milne, Alice S Whittemore, Richard Buchsbaum, Yuyan Liao, Nur Zeinomar, Gillian S Dite, Melissa C Southey, David Goldgar, Graham G Giles, Allison W Kurian, undefined kConFab Investigators, Irene L Andrulis, Esther M John, Mary B Daly, Saundra S Buys, Kelly-Anne Phillips, John L Hopper, et al.

Journal article  |  2021  |  J Natl Cancer Inst

BACKGROUND: Clinical guidelines often use predicted lifetime risk from birth to define criteria for making decisions regarding bre..

Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.

Wanyuan Cui, Prudence A Francis, Sherene Loi, Martha Hickey, Catharyn Stern, Lumine Na, Ann H Partridge, Sibylle Loibl, Richard A Anderson, Karla J Hutt, Louise A Keogh, Kelly-Anne Phillips

Journal article  |  2021  |  J Natl Cancer Inst

BACKGROUND: Loss of ovarian function is a recognized adverse effect of chemotherapy for breast cancer, and of great importance to ..

Survival from breast cancer in women with a BRCA2 mutation by treatment

D Gareth Evans, Kelly-Anne Phillips, Roger L Milne, Robert Fruscio, Cezary Cybulski, Jacek Gronwald, Jan Lubinski, Tomasz Huzarski, Zerin Hyder, Claire Forde, Kelly Metcalfe, Leigha Senter, Jeffrey Weitzel, Nadine Tung, Dana Zakalik, Maria Ekholm, Ping Sun, Steven A Narod

Journal article  |  2021  |  BRITISH JOURNAL OF CANCER

BACKGROUND: The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to es..

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Juliette Coignard, Michael Lush, Jonathan Beesley, Tracy A O'Mara, Joe Dennis, Jonathan P Tyrer, Daniel R Barnes, Lesley McGuffog, Goska Leslie, Manjeet K Bolla, Muriel A Adank, Simona Agata, Thomas Ahearn, Kristiina Aittomaeki, Irene L Andrulis, Hoda Anton-Culver, Volker Arndt, Norbert Arnold, Kristan J Aronson, Banu K Arun, et al.

Journal article  |  2021  |  NATURE COMMUNICATIONS

Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants hav..

Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians

Courtney Macdonald, Danielle Mazza, Martha Hickey, Morgan Hunter, Louise A Keogh, Sandra C Jones, Christobel Saunders, Stephanie Nesci, Roger L Milne, Sue-Anne Mclachlan, John L Hopper, Michael L Friedlander, Jon Emery, Kelly-Anne Phillips

Journal article  |  2021  |  JNCI CANCER SPECTRUM

Background: This study examined why women and doctors screen for ovarian cancer (OC) contrary to guidelines. Methods: Surveys, bas..

CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

Nichola Johnson, Sarah Maguire, Anna Morra, Pooja Middha Kapoor, Katarzyna Tomczyk, Michael E Jones, Minouk J Schoemaker, Clare Gilham, Manjeet K Bolla, Qin Wang, Joe Dennis, Thomas U Ahearn, Irene L Andrulis, Hoda Anton-Culver, Natalia N Antonenkova, Volker Arndt, Kristan J Aronson, Annelie Augustinsson, Caroline Baynes, Laura E Beane Freeman, et al.

Journal article  |  2021  |  BRITISH JOURNAL OF CANCER

BACKGROUND: Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cance..

Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians

Courtney Macdonald, Christobel M Saunders, Louise A Keogh, Morgan Hunter, Danielle Mazza, Sue-Anne Mclachlan, Sandra C Jones, Stephanie Nesci, Michael L Friedlander, John L Hopper, Jon D Emery, Martha Hickey, Roger L Milne, Kelly-Anne Phillips

Journal article  |  2021  |  CANCER PREVENTION RESEARCH

Guidelines endorse the use of chemoprevention for breast cancer risk reduction. This study examined the barriers and facilitators ..

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cecile LePage, Matthew J Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, Zhongyue Xing, Prue Allan, David DL Bowtell, Anne-Marie Mes-Masson, Diane M Provencher, Kurosh Rahimi, Linda E Kelemen, Peter A Fasching, Jennifer A Doherty, Marc T Goodman, Ellen L Goode, Suha Deen, Paul DP Pharoah, et al.

Conference Proceedings  |  2021  |  MODERN PATHOLOGY

TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimi..

Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk

Iris Kramer, Maartje J Hooning, Nasim Mavaddat, Michael Hauptmann, Renske Keeman, Ewout W Steyerberg, Daniele Giardiello, Antonis C Antoniou, Paul DP Pharoah, Sander Canisius, Zumuruda Abu-Ful, Irene L Andrulis, Hoda Anton-Culver, Kristan J Aronson, Annelie Augustinsson, Heiko Becher, Matthias W Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, et al.

Journal article  |  2020  |  AMERICAN JOURNAL OF HUMAN GENETICS

Previous research has shown that polygenic risk scores (PRSs) can be used to stratify women according to their risk of developing ..